Loading
Life sciences · Journal article
Frontiers in Immunology · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immunocytokines (ICs) are engineered biologics comprising a fusion of cytokines to antibodies, designed to deliver targeted cytokines to diseased tissues and mitigate the severe safety challenges associated with systemic cytokine therapy. A rapidly growing number of clinical trials have evaluated ICs, largely based on IL-2, IL-12, and TNF-α, across multiple cancer indications. Although these therapeutics often show improved safety profiles compared to systemic cytokine therapy, clinically relevant toxicities can still occur, including vascular leak syndrome (VLS), hypotension, cytokine release syndrome (CRS), cytopenias, hepatic injury, and local antigen-directed inflammatory toxicities. Although many of these adverse events are manageable, further attenuation is essential to achieve optimal efficacious dosing and to enable combination regimens. Mechanistically, IC toxicities arise through the contribution of both the antibody-mediated target binding and the cytokine moiety. These dual contributors therefore necessitate modality-specific safety considerations. In this focused narrative review, we discuss safety risks associated with clinically advanced IL-2, IL-12 and TNF-α-based ICs, outline potential underlying mechanisms and highlight cytokine- and format-specific factors. We further discuss selected non-clinical mitigation strategies, immunogenicity and translational safety considerations, and outline future directions for developing safer next-generation ICs.